H. Chevrou‐Séverac

Current recommendations on the estimation of transition probabilities in Markov cohort models for use in health care decision-making: a targeted literature review

D. Trueman, E. Olariu, K. Cadwell, 2017, ClinicoEconomics and outcomes research : CEOR.

Assessing the return on investments (cost-benefits) in prevention in Switzerland : a feasibility study

S. Wieser, U. Brügger, A. Holly, 2007 .

Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

A. Bergman, H. Chevrou‐Séverac, Michele R. Wilson, 2018, The European Journal of Health Economics.

Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care

S. Paisley, J. Brazier, D. Rowen, 2017, PharmacoEconomics.

Economic grand rounds: Financial burden of medical care and risk of forgoing care among Europeans with depressive symptoms.

H. Chevrou‐Séverac, I. Peytremann-Bridevaux, H. Chevrou-Séverac, 2008, Psychiatric services.

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

M. Ratcliffe, H. Chevrou‐Séverac, E. Adkins, 2017, ClinicoEconomics and outcomes research : CEOR.

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting

L. Bullinger, J. Hernández-Rivas, P. Williamson, 2019, Trials.

Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores

L. Longworth, H. Chevrou‐Séverac, A. Meunier, 2021, Applied Health Economics and Health Policy.